Anthem Biosciences Share Price Jumps 27% on Market Debut

Market Debut Performance

Anthem Biosciences made a strong entry into the stock market on Monday, July 21, with its shares listing at a notable premium on both exchanges.

• BSE Listing Price: ₹723.10
• NSE Listing Price: ₹723.05
• Issue Price: ₹570
• Listing Premium: 26.85%

The premium was nearly in line with grey market expectations, which had suggested a gain of around 31.40%.

IPO Details and Investor Response

The ₹3,395 crore IPO of Anthem Biosciences was open for public subscription between July 14 and July 16 and was entirely an Offer for Sale (OFS).

• Overall Subscription: 67.42 times
• QIB Subscription: 192.80 times
• NII Subscription: 44.70 times
• Retail Subscription: 5.98 times
• Anchor Investment Raised: ₹1,016 crore

Importantly, as it was a pure OFS, no proceeds will go to the company, except for covering the offer-related expenses. All the funds raised from the issue will go to the selling shareholders.

Company Overview

Incorporated in 2006, Anthem Biosciences is a Contract Research, Development, and Manufacturing Organization (CRDMO). It offers comprehensive solutions to pharmaceutical and biotech companies, including:

• Early drug discovery
• Development and scale-up
• Commercial manufacturing

The company uses an integrated operational model, which aims to simplify complex drug development processes and ease regulatory compliance burdens for clients.

Summary

The Anthem Biosciences share price surged nearly 27% on its market debut, reflecting strong investor sentiment and alignment with grey market expectations. The IPO, which saw a high subscription rate across categories, marks a significant milestone for the CRDMO firm. Although the company will not retain any IPO proceeds due to the nature of the offer, its successful listing reflects the market's confidence in its business model and industry presence.